Autoimmune clinical manifestations following intravesical bacillus calmette-guérin and interferon alpha 2b immunotherapy for superficial bladder cancer

Current Urology

Volumn 3, Issue 1, 2009, Pages 36-40

  Vasdev, Nikhil ^a,b   Esuvaranathan, Kesavan ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Autoimmunity; Bacillus Calmette Gu rin; Bladder cancer; Interferon alpha 2b

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA2B INTERFERON; BCG VACCINE; C REACTIVE PROTEIN; IBUPROFEN; ISONIAZID; NAPROXEN; PREDNISOLONE;

ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COXITIS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INCIDENCE; IRITIS; KNEE ARTHRITIS; MAJOR CLINICAL STUDY; MALE; POLYARTHRITIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS;

EID: 77953401700     PISSN: 16617649     EISSN: 16617657     Source Type: Journal    
DOI: 10.1159/000189679     Document Type: Article

References (34)

1. Alexandroff AB, Jackson AM, O'Donnell MA, James K: BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999;353:1689-1694.
2. O'Donnell MA, DeWolf WC: Bacillus Calmette-Guerin immunotherapy for super-fcial bladder cancer: New aspects for an old warhorse. Surg Oncol Clin N Am 1995;4:189-202.
3. O'Donnell MA: Use of inravesical BCG in the treatment of superfcial bladder cancer; in Droller MJ (ed): Bladder cancer: current diagnosis and treatment. Totowa, NJ,Human Press, 2001, pp 225-265.
4. Morales A, Nickel JC: Immunotherapy for superfcial bladder cancer. A developmental and clinical overview. Urol Clin North Am 1992;19:549-556.
5. Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superfcial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-1970.
6. Izumi AK, Matsunaga J: BCG vaccine-induced lupus vulgaris. Arch Dermatol 1982; 118:171-172.
7. Steg A, Adjiman S, Debre B: BCG therapy in superfcial bladder tumours- complications and precautions. Eur Urol 1992;21(sup-pl):35-40.
8. Lamm DL, Van Der Meijden AD, Morales A, Brosman SA, Catalona WJ, Herr HW, Solo-way MS, Steg A, Debruyne FM: Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in su-perfcial bladder cancer. J Urol 1992;147:596-600.
9. Witjes JA: Management of BCG failures in superfcial bladder cancer: a review. Eur Urol 2006;49:790-797.
10. O'Donnell MA, Boehle A: Treatment options for BCG failures. World J Urol 2006;24:481-487.
11. Prescott S, James K, Hargreave TB, Ch-isholm GD, Smyth JF: Intravesical BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992;147:1636-1642.
12. Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T: Intravesical instillation therapy with bacillus Calmette-Guérin for superfcial bladder cancer: study of the mechanism of bacillus Calmette-Guérin im-munotherapy. Int J Urol 2007;14:140-146.
13. Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S: Changes in urinary cytokine and solubile intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol 1995;99:369-375.
14. Bercovich E, Deriu M, Manferrari F: BCG versus BCG plus interferon alpha-interferon 2b immunotherapy in superfcial bladder cancer. Arch Ital Urol Androl 1995;67:257-260.
15. Malmström PU, Wijkström H, Lundholm C, Wester K, Busch C, Norlén BJ: 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superf-cial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999; 161:1124-1127.
16. van der Meijden AP, Sylvester RJ, Ooster-linck W, Hoeltl W, Bono AV; EORTC Geni-to-Urinary Tract Cancer Group: Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased tox-icity: results from a European Organisation for Research and Treatment of Cancer Geni-to-Urinary Group Phase III Trial. Eur Urol 2003;44:429-434.
17. Stricker P, Pryor K, Nicholson T, Goldstein D, Golovsky D, Ferguson R, Nash P, Ehsman S, Rumma J, Mammen G, Penny R: Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superfcial bladder cancer. Urology 1996;48:957-961.
18. Hidoussi A, Slama A, Jaidane M, Zakhama W, Youssef A, Ben Sorba N, Mosbah AF: Eosinophilic cystitis induced by bacillus Calmette-Guerin (BCG) intravesical instillation. Urology 2007;70:591.e9-10.
19. Orikasa K, Namima T, Ota S, Miura M, Hama H, Kimura N, Ohnuma T: Acute eo-sinophilic pneumonia associated with intra-vesical bacillus Calmette-Guérin therapy of carcinoma in situ of the bladder. Int J Urol 2003;10:622-624.
20. Downs TM, Szilvasi A, O'Donnell MA: Pharmacological biocompatibility between intravesical preparations of BCG and inter-feron alpha 2B. J Urol 1997;158:2311-2315.
21. Tinazzi E, Ficarra V, Simeoni S, Peterlana D, Lunardi C: Reactive arthritis following BCG immunotherapy for bladder cancer. Clin Rheumatol 2005;24:425-427.
22. Hogarth MB, Thomas S, Seifert MH, Tariq SM: Reiter's syndrome following intravesi-cal BCG. Postgrad Med J 2000;76;791-793.
23. Lamm DL, Steg A, Boccon-Gibod L, Morales A, Hanna MG Jr, Pagano F, Alfthan
24. Brosman S, Fisher HA, Jakse G, et al: Compilations of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 1989;310:335-355.
25. Di Stasi SM, Virgili G, Vespasiani G, Porena M, Micali F: Intralesional alpha interferon therapy in papillary superfcial transitional cell carcinoma of the bladder. A pilot study. Br J Urol 1993;71:422-426.
26. Murata H, Adachi Y, Ebitsuka T, Chino Y, Takahash R, Hayashi T, Goto D, Matsumoto
27. Tsutsumi A, Akaza H, Sumida T: Reiter's syndrome following intravesical bacillus Calmette-Guérin treatment for superfcial bladder carcinoma: report of six cases. Mod Rheumatol 2004;14:82-86.
28. Pearson CM: Experimental models in rheumatoid disease. Arthritis Rheum 1964;7:80-86.
29. Dall L, Long L, Stanford J: Poncet's disease: tuberculous rheumatism. Rev Infect Dis 1989;11:105-107.
30. Brown DH, Wagner TT, Bahnson RR: Inter-ferons and bladder cancer. Urol Clin North Am 2000;27:171-178.
31. Johnson DM, Hayat SQ, Burton GV: Rheumatoid arthritis complicating adjuvant inter-feron-alpha therapy for malignant melanoma. J Rhematology 1999;26:1009-1010.
32. Maccari S, Bassi C, Giovannini AG, Planch-er AC: A case of arthropathy and hypothy-roidism during recombinant alpha-interferon therapy. Clin Rheumatol 1991;10:452-454.
33. Mas AJ, Romera M, Valverde Garcia JM: Articular manifestations after the administration of intravesical BCG. Joint Bone Spine 2002;69:92-93.
34. De Boer LC, Steerenberg PA, Van der Mei-jden PM, Van Klingeren B, De Jong WH, Elgersma A, Debruyne FM, Ruitenberg EJ: Impaired immune response by Isoniazid treatment during intravesical BCG administration in the guinea pig. J Urol 1992;148:1577-1582.